{"entity":{"id":"imunon","kind":"company","name":"Imunon","aka":["IMUNON, Inc.","Celsion Corporation","Celsion"],"tldr":"Imunon, formerly Celsion, is a New Jersey company developing a DNA-based interleukin-12 immunotherapy for ovarian cancer after its heat-activated liposomal doxorubicin, ThermoDox, failed in liver cancer.","summary":"Imunon, which renamed itself from Celsion Corporation in 2022, is listed on Nasdaq. Its earlier lead product ThermoDox, a heat-sensitive liposomal doxorubicin released by radiofrequency ablation, failed the phase 3 HEAT and OPTIMA trials in hepatocellular carcinoma. The company now develops IMNN-001 (formerly GEN-1), a plasmid encoding interleukin-12 delivered into the abdomen to treat advanced ovarian cancer alongside chemotherapy, which is in phase 3. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.imunon.com"},{"label":"ClinicalTrials.gov: trials led by Imunon","url":"https://clinicaltrials.gov/search?lead=Imunon"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Celsion_Corporation"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["ovarian","hcc"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06915025","nct05739981","nct03393884"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Lawrenceville, NJ","country":"US","companyType":"biotech","website":"https://www.imunon.com","stage":"public","investors":[],"funding":[]},"route":"/companies/imunon/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"trial":[{"id":"nct06915025","kind":"trial","name":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat","route":"/trials/nct06915025/"},{"id":"nct05739981","kind":"trial","name":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","route":"/trials/nct05739981/"},{"id":"nct03393884","kind":"trial","name":"Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)","route":"/trials/nct03393884/"}]}}